Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharvaris N.V.

14.82
-0.2700-1.79%
Post-market: 14.820.00000.00%16:05 EDT
Volume:22.09K
Turnover:333.06K
Market Cap:807.59M
PE:-5.76
High:15.44
Open:15.10
Low:14.70
Close:15.09
Loading ...

Pharvaris NV reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
09 Apr

Stock Track | Pharvaris N.V. Surges 5.22% in Pre-market Following Q4 Earnings Release

Stock Track
·
08 Apr

Pharvaris Reports 2024 Financial Results and Business Progress

TIPRANKS
·
08 Apr

Pharvaris Positioned for Growth with Successful Trial and Strong Financials, Analyst Projects Significant Market Expansion

TIPRANKS
·
08 Apr

Pharvaris (PHVS) Receives a Buy from Morgan Stanley

TIPRANKS
·
07 Apr

Pharvaris Reports 2024 Financial Results and Advances HAE Treatment Studies

TIPRANKS
·
07 Apr

Pharvaris Q4 2024 GAAP EPS €(0.64) Beats €(0.71) Estimate, Cash Balance Of €281M

Benzinga
·
07 Apr

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

THOMSON REUTERS
·
07 Apr

Pharvaris Nv Q4 Shr View EUR -0.72 -- Lseg Ibes Data

THOMSON REUTERS
·
07 Apr

Pharvaris Nv Qtrly Loss per Share of €0.64

THOMSON REUTERS
·
07 Apr

Pharvaris NV expected to post a loss of 72 cents a share - Earnings Preview

Reuters
·
05 Apr

Pharvaris Says EU Orphan Designation Received for Deucrictibant

MT Newswires Live
·
01 Apr

Pharvaris says EC grants orphan designation to deucrictibant

TIPRANKS
·
01 Apr

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

THOMSON REUTERS
·
01 Apr

Pharvaris Price Target Maintained With a $55.00/Share by Citizens Capital Markets

Dow Jones
·
03 Mar

Pharvaris reports safety and efficacy data of deucrictibant

TIPRANKS
·
03 Mar

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS) and Blueprint Medicines (BPMC)

TIPRANKS
·
03 Mar

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Simply Wall St.
·
26 Feb

Morgan Stanley Remains a Buy on Pharvaris (PHVS)

TIPRANKS
·
24 Feb

Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)

TIPRANKS
·
18 Feb